GleamWall
中文EN

BBLG Bone Biologics Corp

Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1419554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY28.0%
TTM EPS YoY57.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-47.5%
ROA-44.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets7.5%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$242,569$308,747$141,597$257,197$187,808$191,608$423,576$1.10M
SG&A expense$423,771$499,359$663,457$475,908$527,466$556,467$614,910$450,367
Operating income-$666,340-$808,106-$805,054-$733,105-$715,274-$748,075-$1.04M-$1.55M
Net income-$617,651-$773,702-$765,988-$684,643-$666,737-$740,519-$1.02M-$1.52M
EPS (basic)-0.17-0.43-0.43—-0.37-1.33-1.92—
EPS (diluted)-0.17-0.43-0.43—-0.37-1.33-1.92—
Weighted avg. shares (diluted)3.74M1.80M1.80M—1.80M557,787530,618—
Balance sheet
Cash & equivalents$6.09M$4.03M$4.53M$5.33M$6.05M$6.64M$2.75M$3.33M
Current assets$6.43M$4.44M$4.98M$5.80M$6.35M$7.00M$3.16M$3.86M
Total assets$6.43M$4.44M$4.98M$5.80M$6.35M$7.00M$3.16M$3.86M
Current liabilities$480,775$512,018$309,386$418,587$334,282$406,142$251,158$377,712
Total liabilities$480,775$512,018$309,386$418,587$334,282$406,142$251,158$377,712
Shareholders' equity$5.95M$3.92M$4.67M$5.38M$6.02M$6.60M$2.91M$3.48M
Shares outstanding3.39M1.81M1.80M1.80M1.80M1.69M3.27M492,417
Cash flow statement
Operating cash flow-$532,275-$518,440-$804,282-$714,762-$591,384-$458,879-$926,125-$1.35M
Financing cash flow$2.59M——$0$0$4.35M$347,549$1.11M
Stock-based compensation$3,425$8,253$23,505$45,674$87,180$72,899$50,605$100,754

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.